Utah Medicaid Pharmacy and Therapeutics Committee Drug

Total Page:16

File Type:pdf, Size:1020Kb

Utah Medicaid Pharmacy and Therapeutics Committee Drug Utah Medicaid Pharmacy and Therapeutics Committee Drug Class Review Non-Vitamin K Anticoagulants for Venous Thromboembolism and Nonvalvular Atrial Fibrillation Direct Thrombin Inhibitors Dabigatran (Pradaxa, generic) Desirudin (Iprivask) Direct Factor Xa Inhibitors Apixaban (Eliquis) Betrixaban (Bevyxxa) Edoxaban (Savaysa) Fondaparinux (Arixtra) Rivaroxaban (Xarelto) Low Molecular Weight Heparins Dalteparin (Fragmin, generic) Enoxaparin (Lovenox, generic) AHFS Classification: 20:12.04.12 Direct Thrombin Inhibitors, 20:12.04.14 Direct Factor Xa Inhibitors, 20:12.04.16 Heparins Final Report October 2018 Review prepared by: Elena Martinez Alonso, B.Pharm., MSc MTSI, Medical Writer Valerie Gonzales, Pharm.D., Clinical Pharmacist Vicki Frydrych, B.Pharm., Pharm.D., Clinical Pharmacist Lauren Heath, Pharm.D., MS, BCACP, Assistant Professor (Clinical) Michelle Fiander, MA, MLIS, Research Assistant Professor, Evidence Synthesis Librarian Joanne LaFleur, PharmD, MSPH, Associate Professor University of Utah College of Pharmacy University of Utah College of Pharmacy, Drug Regimen Review Center Copyright © 2018 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved Contents Executive Summary ........................................................................................................................ 3 Introduction ..................................................................................................................................... 7 Table 1. FDA-Approved Indications for Non-Vitamin K Anticoagulants ............................. 8 Table 2. Dosage Recommendations for Non-Vitamin K Anticoagulants ............................... 9 Methods......................................................................................................................................... 12 Disease Overview ..................................................................................................................... 14 Guidelines Recommendations and Treatment Strategies ......................................................... 15 Table 3. Clinical Guidelines for Non-vitamin K Anticoagulants ......................................... 16 Pharmacology ............................................................................................................................... 19 Table 4: Pharmokinetics of Non-vitamin K Anticoagulants................................................. 19 Drug-drug Interactions .................................................................................................................. 20 Special Populations ....................................................................................................................... 21 Table 5: Special Population Information for Non-vitamin K Anticoagulants ...................... 22 Head-to Head Efficacy and Safety Comparisons .......................................................................... 25 Figure 1. PRISMA Flow Chart for Publication Screening ................................................... 25 Figure 2. Direct Comparative Efficacy Evidence of Direct Anticoagulants versus LMWHs for VTE Treatment and Prevention....................................................................................... 26 Summary of Guideline Recommendations and Findings Reported in SR/MAs and RCTs ..... 27 Table 6. Summary of Evidence Findings and Treatment Options for NVAF and VTE patients .................................................................................................................................. 27 Findings Reported in SR/MAs and RCTs for Venous Thromboembolism .............................. 28 Findings Reported in SR/MAs and RCTs for Non-valvular Atrial Fibrillation ....................... 33 Safety ............................................................................................................................................ 34 Table 7. Labeled Black Box Warnings and Most Common Adverse Events with Non- vitamin K Anticoagulants ..................................................................................................... 35 Summary ....................................................................................................................................... 36 References ..................................................................................................................................... 38 Appendix A: Literature Search Strategies .................................................................................... 43 Appendix B: List of Excluded Studies.......................................................................................... 47 Appendix C: Direct Evidence from Systematic Reviews ............................................................. 49 Appendix D: Randomized Controlled Trials Identified in the Included Systematic Reviews ..... 60 Appendix E: Characteristics of the Main Randomized Controlled Trials Identified in the Included Systematic Reviews ...................................................................................................................... 63 2 Executive Summary Introduction: Anticoagulation is indicated for the treatment of acute venous thromboembolism (VTE), reduction in the risk of recurrent VTE, VTE prophylaxis following major surgery (eg, total hip and knee replacement), and VTE prophylaxis in patients hospitalized for an acute medical illness. Anticoagulation is also indicated for stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation (NVAF). The main objective of anticoagulation is to prevent thromboembolism and further complications. Many anticoagulant therapies are currently available in the United States. This report evaluates head-to-head efficacy and safety comparisons among the following non-vitamin K anticoagulants: 2 direct thrombin inhibitors (dabigatran and desirudin), 5 direct factor Xa inhibitors (apixaban, betrixaban, edoxaban, fondaparinux, and rivaroxaban), and 2 low molecular weight heparins (LMWHs, dalteparin and enoxaparin). Each of the agents are indicated for VTE treatment or prophylaxis in various patient subgroups at once or twice daily dosing depending on the agent and indication. Apixaban, dabigatran, edoxaban, and rivaroxaban are additionally indicated for the prevention of stroke and systemic embolism in patients with NVAF. Dabigatran and the factor Xa inhibitors apixaban, betrixaban, edoxaban, and rivaroxaban are available as oral formulations. Desirudin, fondaparinux, and the 2 LMWHs are available as parenteral subcutaneous formulations. Although dabigatran and factor Xa inhibitors offer advantages over the traditional anticoagulant warfarin (ie, no need for routine laboratory monitoring, fixed oral dosing, rapid onset of action, and fewer drug interactions), individualization of therapy is important. Drug-drug interactions and renal function may limit the use of some agents. The 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) guideline for the management of atrial fibrillation recommends oral anticoagulants for patients with NVAF who have history of stroke, transient ischemic attack, or CHA2DS2- . Warfarin, dabigatran, rivaroxaban, or apixaban are recommended as first-line anticoagulant therapy options. VASc score ≥ 2 For acute treatment of VTE, the 2016 American College of Chest Physicians (CHEST) guideline recommends dabigatran or the oral factor Xa inhibitors, apixaban rivaroxaban, or edoxaban in preference to vitamin K antagonist (VKA) therapy (ie, warfarin) for at least three months following deep vein thrombosis (DVT) of the leg or pulmonary embolism (PE) in patients without cancer. In cancer patients with DVT of the leg or PE (“cancer- associated thrombosis”), LMWHs for at least 3 months are preferred over VKA therapy, dabigatran, rivaroxaban, apixaban, or edoxaban. Some patients may continue extended treatment beyond 3 months either with the initial therapy or alternative therapy according to the patient’s response or preferences. For VTE prophylaxis following THR or TKR surgery, the 2012 CHEST guideline recommends LMWH therapy for at least 10 to 14 days over other agents (ie, fondaparinux, 3 dabigatran, apixaban, rivaroxaban, VKA, unfractionated heparin, aspirin, and intermittent pneumatic compression device). In patients declining injectable formulations, apixaban or dabigatran are recommended. Extended-thromboprophylaxis is recommended for up to 35 days. For VTE prophylaxis in acutely ill hospitalized medical patients at high risk of thrombosis, the 2012 CHEST guideline recommends LMWH, unfractionated heparin, or fondaparinux during the hospital stay or period of immobilization. Efficacy: After performing a systematic literature search for systematic review/meta- analysis (SR/MA) and randomized controlled trial (RCT) evidence containing head-to-head efficacy and safety comparisons among non-vitamin K anticoagulants, 16 publications were identified. Twelve additional publications were found by checking the reference lists of related articles. Non-valvular atrial fibrillation For the prevention of stroke or systemic embolism in patients with NVAF, no head-to-head RCTs comparing direct thrombin inhibitors with factor Xa inhibitors or comparing factor Xa inhibitors with one another were identified. Venous Thromboembolism For the treatment or prevention of VTE, no head-to-head RCTs comparing direct thrombin inhibitors with factor Xa inhibitors or comparing factor Xa inhibitors with one
Recommended publications
  • Extended-Duration Betrixaban Versus Shorter-Duration Enoxaparin for Venous Thromboembolism Prophylaxis in Critically Ill Medical
    Intensive Care Med (2019) 45:477–487 https://doi.org/10.1007/s00134-019-05565-6 ORIGINAL Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy Gerald Chi1* , C. Michael Gibson2, Arzu Kalayci1, Alexander T. Cohen3, Adrian F. Hernandez4, Russell D. Hull5, Farima Kahe1, Mehrian Jafarizade1, Sadaf Sharfaei1, Yuyin Liu6, Robert A. Harrington7 and Samuel Z. Goldhaber8 © 2019 Springer-Verlag GmbH Germany, part of Springer Nature Abstract Purpose: To assess the efcacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxis among criti- cally ill patients. Methods: The APEX trial randomized 7513 acutely ill hospitalized patients to betrixaban for 35–42 days or enoxa- parin for 10 4 days. Among those, 703 critically ill patients admitted to the intensive care unit were included in the analysis, and± 547 patients who had no severe renal insufciency or P-glycoprotein inhibitor use were included in the full-dose stratum. The risk of VTE, bleeding, net clinical beneft (composite of VTE and major bleeding), and mortality was compared at 35–42 days and at 77 days. Results: At 35–42 days, extended betrixaban reduced the risk of VTE (4.27% vs 7.95%, P 0.042) without causing excess major bleeding (1.14% vs 3.13%, P 0.07). Both VTE (3.32% vs 8.33%, P 0.013) and= major bleeding (0.00% vs 3.26%, P 0.003) were decreased in the full-dose= stratum. Patients who received= betrixaban had more non-major bleeding= than enoxaparin (overall population: 2.56% vs 0.28%, P 0.011; full-dose stratum: 3.32% vs 0.36%, P 0.010).
    [Show full text]
  • Standard-Dose Apixaban After Very Low-Dose Thrombolysis for Acute Intermediate-High Risk Acute Pulmonary Embolism
    SAFE-LYSE | STUDY PROTOCOL Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis Title: for Acute Intermediate-high Risk Acute Pulmonary Embolism Short Title: SAFE-LYSE Protocol Version: Issue Date: 28/AUG/2019 Principal Victor Tapson1,2, Aaron Weinberg1,2 Investigators: Sub Investigators: Sam Torbati1, Susan Jackman1, Niree Hindoyan1, Joseph Meza1 1Cedars-Sinai Medical Center 8700 Beverly Blvd Los Angeles, CA 90048 Affiliations: 2Cedars-Sinai Medical GrouP 200 N. Robertson Blvd. Beverly Hills, CA 90211 Victor TaPson 8730 Alden Drive, W155 Primary Contact: Los Angeles, CA 90048 (919) 971-6441 Investigator-Initiated Bristol-Myers Squibb Company (BMS) Study Funded By: Version 8.0 | Date: 28Aug2019 1 SAFE-LYSE | STUDY PROTOCOL STUDY SYNOPSIS Funding Provided by BMS/Pfizer Alliance Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Protocol Title Acute Intermediate-high Risk Acute Pulmonary Embolism (SAFE-LYSE) Pulmonary embolism (PE) is a major cause of mortality in the United States, with an estimated 100,000 deaths annually and uP to 30% of Patients dying within the first month of diagnosis. Recent guidelines now risk-stratify intermediate-risk PE Patients to intermediate-low and intermediate-high risk categories, but consensus on treatment for those Patients are controversial, as compared to that of high or low-risk Patients. Because of an increased risk of major, non-major, and intracranial bleeding and an uncertain effect on survival and Post-thrombotic complications, thrombolysis is not routinely recommended in the guidelines for intermediate- risk Patients. However, studies have evaluated half-dose (50 mg dose) tissue Plasminogen activator (tPA) and this aPPears to be effective for treating PE with a reduced yet still significant risk of bleeding.
    [Show full text]
  • Thromboprophylaxis for Venous Thromboembolism UHL Guideline
    Guidelines for Pharmacological and Mechanical Thromboprophylaxis for venous thromboembolism. Approved By: Policy and Guideline Committee Date Approved: 12 February 2016 Trust Reference: B9/2016 Version: V4 – 16 August 2019 Policy and Guideline Committee Supersedes: V3 February 2016 Author / Originator(s): Simon Rudge, Venous Thrombosis Nurse Name of Responsible Thrombosis Prevention Committee Committee/Individual: Review Date: August 2022 CONTENTS Section Page 1. Introduction 3 2. Policy Scope 5 VTE Risk Assessment and Pharmacological and Mechanical venous 3. 6 thromboprophylaxis 4. Patient information 8 5. Mechanical thromboprophylaxis. Application and management guide 9 6. Nursing care 12 7. References 12 8. Legal Liability Guideline Statement 12 Appendix 1 Derogation from NICE NG89: VTE risk assessment of 16 & 17yr olds 13 Appendix 2a/2a1/2b/2c VTE risk assessment tools 14-18 Appendix 3 NICE CG92 algorithm for VTE thromboprophylaxis in medical patients 19 Appendix 4 Consensus of risk factors for VTE in surgical patients 20 Appendix 5 UHL and East Midlands approved List of cohort Day Case procedures 21 Appendix 6 Thromboprophylaxis administration guide: Dalteparin 22 Appendix 7 Derogation from NICE NG89: minimum of 7 days low molecular weight 23 heparin for acutely unwell medical patients Appendix 8 Indications for mechanical thromboprophylaxis algorithm 24 Appendix 8a Indications for mechanical thromboprophylaxis with intermittent 25 pneumatic compression devices algorithm Appendix 9 Quick reference guide of NICE NG89 26 Summary of key changes: Addition of procedure specific recommendations from NG89. Inclusion of discharge recommendations. Inclusion of statement regarding medicines of animal origin. Inclusion of training requirements Inclusion of statements of derogation from NG89 Addition of quick reference guide of NG89.
    [Show full text]
  • Hemosil ® Liquid Anti-Xa
    H E M O S I L® LIQUID ANTI-XA Measuring heparin and apixaban: Simple, fast, 24/7 • Liquid formulation, ready-to-use • One-stage, chromogenic anti-Xa assay • Universal calibration for unfractionated heparin (UFH) and low molecular weight heparin (LMWH) • Drug specific calibrators and controls for measurement of apixaban Measuring heparin and apixaban Unfractionated and low molecular weight heparin Heparin is a highly sulfated polysaccharide Laboratory monitoring is extremely important to characterized by a wide molecular weight range and assess the appropriate level of anticoagulation in potent anticoagulant activity. It exists either as UFH patients receiving UFH. Anti-Xa is recommended for or as depolymerized LMWH. UFH and LMWH have measuring both UFH and LMWH. a rapid anticoagulant effect and are used in the prevention and treatment of venous thrombosis and Anti-Xa testing for measuring UFH helps improve acute coronary syndrome. quality of care and patient experience while reducing costs, when compared with APTT testing.1 UFH and LMWH anticoagulant activity occurs when The advantages include: a complex with antithrombin (AT) is formed, • Higher precision potentiating its anticoagulant activity up to • Lower levels of discordant results1,2,4 1,000-fold, which inactivates both thrombin (FIIa) • Faster time to achieve therapeutic levels1,3,4 and Factor Xa (FXa). UFH acts through both FIIa 1,3,4,5 and FXa inhibition, while LMWH is a more efficient • Fewer tests and dosage changes catalyst for FXa inhibition. Direct Xa inhibitors Anticoagulation for patients with venous DOACs do not require routine monitoring. However, thromboembolism (VTE) previously included there are specific instances when an understanding heparin, heparin derivatives and/or oral vitamin K of the DOAC concentration in a patient sample may antagonists.
    [Show full text]
  • The Management of Anticoagulants Using the Chart: – Low Molecular Weight Heparins (I.E
    WA Adult Anticoagulation Medication Chart Overview This presentation will provide an overview of: • The layout of the WA Anticoagulation Medication Chart (WA AMC) • The management of anticoagulants using the chart: – Low Molecular Weight Heparins (i.e. enoxaparin) – Unfractionated heparin (UFH) – Warfarin – Direct oral anticoagulants (DOACs) Anticoagulants – High Risk Medications • Anticoagulants are consistently identified as causing preventable harm to patients. • Top 20 medications involved in medication errors (July 2016 - June 2017) 1. Paracetamol 11. Buprenorphine 2. Enoxaparin 12. Targin (Oxycodone / naloxone) 3. Novorapid Insulin 13. Warfarin 4. Tramadol 14. Diazepam 5. Heparin 15. Tapentadol 6. Fentanyl 16. Metformin 7. Piperacillin & Tazobactam 17. Clonazepam 8. Oxycodone 18. Frusemide 9. Lantus Insulin 19. Hydromorphone 10. Vancomycin 20. Quetiapine • When used in error or omitted, they can cause life-threatening or fatal bleeding or thrombosis. Those most commonly prescribed anticoagulants are: –unfractionated heparin –low-molecular weight heparin (LMWH) • enoxaparin sodium (Clexane®) • dalteparin sodium (Fragmin®) and – warfarin. Direct oral anticoagulants are also available and are being prescribed more frequently: –dabigatran (Pradaxa®) –rivaroxaban (Xarelto®) –apixaban (Eliquis®). Factors that increase the potential for error and harm include: • Low margin for error – over-dose → bleeding – under-dose or omission → thrombosis • Wide variation in individual patient response – multiple indications – wide range and complexity of dosage – frequent dose adjustment/monitoring – interaction with other medicines, herbals, over-the-counter products, food and alcohol. Benefits of the WA Anticoagulant Medication Chart • Provides one chart for all anticoagulant prescriptions to reduce the risk of duplicate prescribing. • Point of care guidelines for initiation, monitoring and reversal of anticoagulants. • Enables the effective achievement of therapeutic levels.
    [Show full text]
  • Dalteparin Sodium Injection) in Children with Venous Thromboembolism with Or Without Malignancies
    FRAG-A001-201 (A6301094) Final Protocol Amendment 9, 18 October 2016 CLINICAL STUDY PROTOCOL A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN® (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES Compound: PN180524 Compound Name : Dalteparin Sodium Injection (Fragmin®) United States (US) Investigational New IND 79,617 Drug (IND) Number: European Clinical Trials Database 2016-000394-21 (EudraCT) #: Protocol Number: FRAG-A001-201 (A6301094) Phase: II Version #: Amendment 9 – 18 October 2016 Pfizer Inc 235 East 42nd Street New York, NY 10017 - Do Not Distribute Page 1 FRAG-A001-201 (A6301094) Final Protocol Amendment 9, 18 October 2016 Document History This amendment incorporates all revisions to date, including amendments made at the request of country health authorities, institutional review boards/ethics committees (IRBs/ECs), etc. Document Date Summary of Changes and Rationale Original Protocol June 23, 2008 Legacy Eisai Inc Protocol Protocol Amendment 1 September 04, 2008 Legacy Eisai Inc Protocol Correction to Amendment 1 January 05, 2009 Legacy Eisai Inc Protocol Protocol Amendment 2 February 20, 2009 Legacy Eisai Inc Protocol Protocol Amendment 3 September 15, 2010 Legacy Eisai Inc Protocol Protocol Amendment 4 September 01, 2011 Legacy Eisai Inc Protocol Protocol Amendment 5 April 21, 2015 Administrative changes per transition of study to Pfizer Inc from Eisai; Updating of Safety Section per Pfizer safety reporting processes and procedures, and other relevant sections per Pfizer Inc processes and procedures. Protocol Amendment 6 09 September 2015 This version was never finalized or submitted and was replaced by Amendment 7. Protocol Amendment 7 18 November 2015 Includes protocol modifications endorsed by FDA in a Type C Meeting conducted on 05 November 2015, including updating age cohort groups, inclusion of all patients with VTE and removal of the central imaging reader and Adjudication Committee.
    [Show full text]
  • Laboratory Monitoring of Direct Oral Anticoagulants (Doacs)
    biomedicines Review Laboratory Monitoring of Direct Oral Anticoagulants (DOACs) Claire Dunois HYPHEN BioMed, Sysmex Group, 95000 Neuville sur Oise, France; [email protected] Abstract: The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous anticoagulant therapies. DOACs directly, selectively, and reversibly inhibit factors IIa or Xa. The coagulation effect follows the plasma concentration–time profile of the respective anticoagulant. The short half-life of a DOAC constrains the daily oral intake. Because DOACs have predictable pharmacokinetic and pharmacodynamic responses at a fixed dose, they do not require monitoring. However in specific clinical situations and for particular patient populations, testing may be helpful for patient management. The effect of DOACs on the screening coagulation assays such as prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT) is directly linked to reagent composition, and clotting time can be different from reagent to reagent, depending on the DOAC’s reagent sensitivity. Liquid chromatography–mass spectrometry (LC-MS/MS) is considered the gold standard method for DOAC measurement, but it is time consuming and requires expensive equipment. The general consensus for the assessment of a DOAC is clotting or chromogenic assays using specific standard calibrators and controls. This review provides a short summary of DOAC properties and an update on laboratory methods for measuring DOACs. Keywords: DOAC; monitoring; screening assays; quantitative assays Citation: Dunois, C. Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). 1. Introduction Biomedicines 2021, 9, 445. https:// Direct oral anticoagulants (DOACs) constitute first-line therapy used for many throm- doi.org/10.3390/biomedicines9050445 boembolic indications, such as prevention and treatment of venous thromboembolism (VTE) and stroke prevention in atrial fibrillation (AF) [1,2].
    [Show full text]
  • Perioperative Management of Patients Treated with Antithrombotics in Oral Surgery
    SFCO/Perioperative management of patients treated with antithrombotic agents in oral surgery/Rationale/July 2015 SOCIÉTÉ FRANÇAISE DE CHIRURGIE ORALE [FRENCH SOCIETY OF ORAL SURGERY] IN COLLABORATION WITH THE SOCIÉTÉ FRANÇAISE DE CARDIOLOGIE [FRENCH SOCIETY OF CARDIOLOGY] AND THE PERIOPERATIVE HEMOSTASIS INTEREST GROUP Space Perioperative management of patients treated with antithrombotics in oral surgery. RATIONALE July 2015 P a g e 1 | 107 SFCO/Perioperative management of patients treated with antithrombotic agents in oral surgery/Rationale/July 2015 Abbreviations ACS Acute coronary syndrome(s) ADP Adenosine diphosphate Afib Atrial Fibrillation AHT Arterial hypertension Anaes Agence nationale d’accréditation et d’évaluation en santé [National Agency for Accreditation and Health Care Evaluation] APA Antiplatelet agent(s) aPTT Activated partial thromboplastin time ASA Aspirin BDMP Blood derived medicinal products BMI Body mass index BT Bleeding Time cAMP Cyclic adenosine monophosphate COX-1 Cyclooxygenase 1 CVA Cerebral vascular accident DIC Disseminated intravascular coagulation DOA Direct oral anticoagulant(s) DVT Deep vein thrombosis GEHT Study Group on Hemostasis and Thrombosis (groupe d’étude sur l’hémostase et la thrombose) GIHP Hemostasis and Thrombosis Interest Group (groupe d’intérêt sur l’hémostase et la thrombose) HAS Haute autorité de santé [French Authority for Health] HIT Heparin-induced thrombocytopenia IANB Inferior alveolar nerve block INR International normalized ratio IV Intravenous LMWH Low-molecular-weight heparin(s)
    [Show full text]
  • Transition of Anticoagulants 2019
    Transition of Anticoagulants 2019 Van Hellerslia, PharmD, BCPS, CACP, Brand Generic Clinical Assistant Professor of Pharmacy Practice, Angiomax bivalirudin Temple University School of Pharmacy, Philadelphia, PA Arixtra fondaparinux Bevyxxa betrixaban Pallav Mehta, MD, Assistant Professor of Medicine, Coumadin warfarin Division of Hematology/Oncology, Eliquis apixaban MD Anderson Cancer Center at Cooper, Camden, NJ Fragmin dalteparin Lovenox enoxaparin Reviewer: Kelly Rudd, PharmD, BCPS, CACP, Pradaxa dabigatran Clinical Specialist, Anticoagulation, Bassett Medical Center, Savaysa edoxaban Cooperstown, NY Xarelto rivaroxaban From To Action Apixaban Argatroban/ Wait 12 hours after last dose of apixaban to initiate parenteral anticoagulant. In cases of Bivalirudin/ high bleeding risk, consider omitting initial bolus when transitioning to heparin infusion. Enoxaparin/ Dalteparin/ Fondaparinux/ Heparin Apixaban Warfarin When going from apixaban to warfarin, consider the use of parenteral anticoagulation as a bridge (eg, start heparin infusion or therapeutic enoxaparin AND warfarin 12 hours after last dose of apixaban and discontinue parenteral anticoagulant when INR is therapeutic). Apixaban affects INR so that initial INR measurements during the transition may not be useful for determining the appropriate dose of warfarin. Apixaban Betrixaban, Wait 12 hours from last dose of apixaban to initiate betrixaban, dabigatran, edoxaban, or Dabigatran, rivaroxaban. Edoxaban, or Rivaroxaban Argatroban Apixaban, Start apixaban, betrixaban, dabigatran,
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Antithrombotic Therapy During Pregnancy
    ARC Journal of Pharmaceutical Sciences (AJPS) Volume 1, Issue 2, July – September 2015, PP 16-20 www.arcjournals.org Antithrombotic Therapy During Pregnancy Sihana Ahmeti Lika1*, Bujar H. Durmishi2, Agim Shabani2, Merita Dauti1, Ledjan Malaj3 1 Faculty of Medical Sciences, Department of Pharmacy, State University of Tetova, Ilindeni Str. n.n., 1200 Tetova, R. of Macedonia [email protected] 2 Faculty of Mathematical - Natural Sciencese, Department of Chemistry, State University of Tetova, Ilindeni Str. n.n., 1200 Tetova, R. of Macedonia 3 Faculty of Pharmacy, Medical University of Tirana, of Albania Abstract: Antithrombotic therapy is the main therapy for acute deep vein thrombosis. The objectives of anticoagulant therapy in the initial treatment are to prevent thrombus extension and early and late recurrences of deep vein thrombosis and pulmonary embolism. The main objective of our study is to analyze the usage of low molecular weight heparins in women, during the period of pregnancy. Our study, represents a retrospective study, which was undertaken during 01 July – 31 December 2013, in the Department of Gynecology and Obstetrics, at Clinical Hospital in Tetova. Among of 817 pregnant women, 277 of them received anticoagulant therapy, respectively Low Molecular Weight Heparins. 119 of them were patients with risky pregnancy and 68 were with the diagnosis Hypercoagulable State. Keywords: Antithrombotics, Deep Vein Thrombosis, Pregnancy, Low Molecular Weight Heparins. Abrevations LMWH Low molecular weight heparins VT venous thromboembolism 1. INTRODUCTION There are two main adverse expriences that are associated with thrombophilia and pregnancy. These are VT and pregnancy complications associated with placental infarction, including miscarriage, intrauterine growth restriction, preeclampsia, abruption, and intrauterine death [1].
    [Show full text]
  • The Role of Direct Oral Anticoagulants in the Management of Venous Thromboembolism Taylor Steuber, Pharmd, BCPS
    REPORT The Role of Direct Oral Anticoagulants in the Management of Venous Thromboembolism Taylor Steuber, PharmD, BCPS enous thromboembolism (VTE), including deep vein ABSTRACT thrombosis (DVT) and pulmonary embolism (PE), occurs in as many as 900,00 people in the United States each Appropriate treatment of venous thromboembolism (VTE) is critical to year, with up to 100,000 Americans dying as a result.1 A minimizing long-term morbidity and mortality. The emergence of direct Vcommon complication, VTE is the most preventable cause of death oral anticoagulants (DOACs) has provided clinicians with expanded in hospitalized patients.2 Once VTE occurs, long-term mortality therapeutic options for patients with VTE, and as a result, updated practice guidelines released by the American College of Chest Physicians is poor, with 25% of patients not surviving 7 days and nearly 40% favor DOACs over traditional anticoagulants, such as warfarin. The newest 3 not surviving the first year. Furthermore, PE with or without DVT DOAC, betrixaban, received FDA approval in 2017, with an indication has been found to be an independent predictor of reduced survival for VTE prophylaxis in hospitalized adults. Additionally, results from the compared with DVT alone.3 Among those who do survive, 30% will XALIA study on the real-world outcomes of rivaroxaban are now available. experience a recurrence of VTE within 10 years.4 A reversal agent for dabigatran, idarucizumab, also received FDA approval in 2017, and other reversal agents are in development. This article Historically, the pathogenesis of VTE has been explained with will provide an overview of current VTE treatment strategies, with an the 3 components of Virchow’s triad: hypercoagulability, hemody- emphasis on the place in therapy of the DOACs.
    [Show full text]